生物制药公司Azitra宣布定价高达约1050万美元私募融资，另可增发最高约2090万美元-动脉网

Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million

CISION 等信源发布 2026-03-20 01:13



可切换为仅中文







Initial funding of approximately $10.5MM in convertible preferred stock and up to an additional $20.9MM upon cash exercise of warrants

初始资金约为 1,050 万美元的可转换优先股，并在权证现金行权时追加高达 2,090 万美元的资金。

Financing marks launch of Azitra new innovative protein and peptide research programs for the cosmetic and cosmeceutical markets

融资标志着Azitra针对化妆品和美容药物市场的新创新蛋白质和肽研究计划的启动。

Leverages untapped potential of Azitra's genetic engineering platform to accelerate time to commercialization

利用Azitra基因工程平台未开发的潜力，加快上市时间

BRANFORD, Conn.

康涅狄格州布兰福德

，

March 19, 2026

2026年3月19日

/PRNewswire/ --

Azitra, Inc.

阿齐特拉公司

(NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has entered into a securities purchase agreement (the 'SPA') with new and existing healthcare focused institutional investors. The financing is for gross proceeds of up to approximately $31.4 million to the Company, including initial gross proceeds of approximately $10.5 million and up to an additional $20.9 million in gross proceeds upon the potential cash exercise of accompanying warrants at the election of the investors.

（纽约证券交易所美国：AZTR），一家专注于开发精准皮肤病学创新疗法的临床阶段生物制药公司，今天宣布已与新的和现有的专注于医疗保健的机构投资者签订了证券购买协议（“SPA”）。此次融资将为公司带来高达约3140万美元的总收益，其中包括约1050万美元的初始总收益，以及在投资者选择行使附带认股权证时可能额外获得的约2090万美元的总收益。

The transaction is expected to close on or about March 20, 2026, subject to the satisfaction of customary closing conditions..

该交易预计将在2026年3月20日左右完成，具体取决于满足惯例的交割条件。

Participating investors include institutional healthcare focused funds, Stonepine Capital and Nantahala Capital as well as other institutional funds and individual healthcare professionals, along with certain Company insiders, including the Company's Chief Executive Officer.

参与的投资者包括专注于医疗保健的机构基金、Stonepine Capital 和 Nantahala Capital，以及其他机构基金和个体医疗保健专业人士，还包括公司的某些内部人士，如公司首席执行官。

The financing enables Azitra to utilize its expertise in skin science and leverage its microbial genetic engineering platform to produce high value proteins and peptides for the cosmetic market. The market for biotech oriented cosmetic ingredients reached $2.3 billion in 2024 and is projected to grow to $3.7 billion by 2030.

这笔融资使 Azitra 能够利用其在皮肤科学方面的专业知识，并利用其微生物基因工程平台为化妆品市场生产高价值的蛋白质和肽。面向生物技术的化妆品原料市场在 2024 年达到 23 亿美元，预计到 2030 年将增长至 37 亿美元。

. The new initiatives drive near term value creation opportunities by streamlining the time to commercialization and opening up a new universe of new potential strategic partners.

新举措通过缩短上市时间并开拓新的潜在战略合作伙伴领域，推动了短期价值创造机会。

'Azitra is thrilled to be accelerating its new program focused on developing its proprietary filaggrin protein and peptide technologies for the consumer, cosmeceutical market,' said Chief Executive Officer, Francisco Salva. 'We are confident these technologies offer an exciting new way to address the appearance of fine lines and wrinkles as well as dry sensitive skin and eczema-like rashes.

“Azitra非常高兴能够加速推进其新项目，专注于为消费者、化妆品市场开发其专有的丝聚蛋白和肽技术，”首席执行官弗朗西斯科·萨尔瓦表示。“我们相信这些技术提供了一种令人兴奋的新方法，可以改善细纹和皱纹的外观，同时还可应对干燥、敏感肌肤以及类似湿疹的皮疹。”

Over the last two decades, research has evolved to understand that such issues are not just the result of immune system overdrive but are commonly driven by a physical barrier deficiency caused by a lack of sufficient filaggrin protein and subsequent breakdown into peptides and natural moisturizing factors.'.

在过去的二十年中，研究已经发展到理解这些问题不仅仅是免疫系统过度反应的结果，而是通常由丝聚蛋白不足导致的物理屏障缺陷所驱动，并随之分解为肽和天然保湿因子。

Pursuant to the terms of the SPA, the Company is selling to investors in the financing an aggregate of (i) 10,470 shares of Series A convertible non-redeemable preferred stock (the 'Series A Preferred Stock'), (ii) Series B warrants (the 'Series B Warrants') to purchase up to 85,101,201 shares of the Company's common stock, par value $0.0001 ('Common Stock') and (iii) Series C warrants (the 'Series C Warrants') to purchase up to 85,101,201 shares of Common Stock, (the Series B Warrants together with the Series C Warrants, the 'Warrants').

根据SPA的条款，公司正在向融资中的投资者出售总计（i）10,470股A系列可转换不可赎回优先股（“A系列优先股”），（ii）B系列认股权证（“B系列认股权证”）用于购买公司最多85,101,201股面值为0.0001美元的普通股（“普通股”），以及（iii）C系列认股权证（“C系列认股权证”）用于购买最多85,101,201股普通股（B系列认股权证与C系列认股权证合称为“认股权证”）。

Each share of Series A Preferred Stock is being sold together with a Series B Warrant to purchase 8,129 shares of Common Stock and a Series C Warrant to purchase 8,129 shares of Common Stock. The Series A Preferred Stock was sold at a purchase price of $1,000 per share to the investors. The Warrants will each have an exercise price of $0.123 per share, subject to adjustment in certain circumstances.

每股A系列优先股与一份可购买8,129股普通股的B系列认股权证和一份可购买8,129股普通股的C系列认股权证一并出售。A系列优先股以每股1,000美元的价格售予投资者。认股权证的行权价格为每股0.123美元，某些情况下可能会进行调整。

In accordance with the terms of the Warrants, in certain circumstances, pre-funded warrants to purchase shares of Common Stock may be issued upon exercise of the Warrants (the 'Pre-Funded Warrants')..

根据权证的条款，在某些情况下，行使权证时可发行预融资购买普通股的权证（“预融资权证”）。

Each share of Series A Preferred Stock will automatically convert into approximately 8,129 shares of Common Stock upon the approval of the Company's stockholders and subject to certain beneficial ownership limitations set by each holder. Holders will receive Pre-Funded Warrants in lieu of shares of Common Stock upon conversion of the Series A Preferred Stock to avoid going above the beneficial ownership limitation.

每股A系列优先股在公司股东批准后，将自动转换为大约8,129股普通股，同时受限于每位持有人设定的某些持股比例限制。在A系列优先股转换时，为避免超过持股比例限制，持有人将获得预融资权证以代替普通股。

The Warrants will be exercisable following the receipt of approval by the Company's stockholders. The Series B Warrants will terminate 18 months following the date of stockholder approval. The Series C Warrants will terminate, subject to certain exceptions, upon the 30th calendar day following the date on which the Company publicly announces data from its planned human cosmetic study testing the effect of the filaggrin technology..

在获得公司股东的批准后，认股权证将可行使。B系列认股权证将在股东批准之日起18个月后终止。C系列认股权证将在公司公开宣布其计划中的人体化妆品研究测试丝聚蛋白技术效果的数据后的第30个日历日终止，但某些例外情况除外。

The issuance of the securities is being made pursuant to exemptions from the registration requirements of the federal and state securities laws. Pursuant to the transaction documents, the Company must register the resale of the shares of common stock issuable upon conversion of the Series A Preferred Stock and exercise of the Warrants..

证券的发行是根据联邦和州证券法的注册要求豁免进行的。根据交易文件，公司必须注册因转换A系列优先股和行使认股权证而可发行的普通股的转售。

The Company intends to use the initial net proceeds from the financing, together with the Company's existing cash and cash equivalents to provide financing for research and development, general corporate expenses, and working capital needs.

公司拟将此次融资的初始净收益与公司现有的现金和现金等价物一起用于研发、一般公司开支及营运资金需求的融资。

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售或要约购买本次发行证券的要约，也不得在任何州或其他司法管辖区进行此类证券的销售，如果在该州或其他司法管辖区未根据其证券法进行注册或资格认证前，此类要约、招揽或销售将属违法。

About Azitra, Inc.

关于Azitra公司

Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. The Company's lead program, ATR-12, uses an engineered strain of

Azitra公司是一家处于临床阶段的生物制药公司，专注于开发用于精准皮肤病学的创新疗法。该公司的主要项目ATR-12使用了经过工程改造的菌株。

S. epidermidis

表皮葡萄球菌

designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound lifelong challenges. The ATR-12 program includes a Phase 1b clinical trial in adult Netherton syndrome patients.

旨在治疗尼特顿综合症，这是一种罕见的慢性皮肤病，目前尚无获批的治疗方案。尼特顿综合症在婴儿期可能是致命的，活过一年的患者将面临深远的终身挑战。ATR-12项目包括针对成年尼特顿综合症患者进行的1b期临床试验。

ATR-04, Azitra's additional advanced program, ATR-04, utilizes another engineered strain of .

ATR-04，Azitra的另一个高级附加项目，ATR-04，利用了另一种工程菌株。

S. epidermidis

表皮葡萄球菌

for the treatment of EGFR inhibitor ('EGFRi') associated rash. Azitra has received Fast Track designation from the FDA for EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash. The ATR-12 and ATR-04 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic products that includes a microbial library comprised of approximately 1,500 bacterial strains.

用于治疗表皮生长因子受体抑制剂（“EGFRi”）相关皮疹。Azitra 已获得 FDA 对 EGFRi 相关皮疹的快速通道资格，该疾病在美国影响约 15 万人。Azitra 针对 EGFRi 相关皮疹的 ATR-04 项目已获得开放性新药临床试验申请（IND）。ATR-12 和 ATR-04 项目源于 Azitra 的专有平台，该平台包括工程化蛋白和局部活体生物治疗产品，并拥有一个包含约 1,500 种细菌菌株的微生物库。

The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the library of strains for drug like molecules. Azitra is also developing its proprietary filaggrin protein and peptide technologies for the consumer, cosmeceutical market. The new initiative is the first amongst others, which aim to leverage Azitra's microbial genetic engineering platform to manufacture innovative proteins and peptides for the cosmetic and research markets.

该平台通过人工智能和机器学习技术进行增强，这些技术分析、预测并帮助筛选菌株库中的类药物分子。Azitra 还在为消费者和美容市场开发其专有的丝聚蛋白和肽技术。这项新举措是首个旨在利用 Azitra 的微生物基因工程平台，为化妆品和科研市场制造创新蛋白质和肽的项目。

For more information, please visit .

欲了解更多信息，请访问。

https://azitrainc.com

。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will,' and variations of these words or similar expressions that are intended to identify forward-looking statements.

本新闻稿包含1995年《私人证券诉讼改革法案》（经修订）意义上的前瞻性陈述。这些陈述可以通过诸如“旨在”、“预期”、“相信”、“可能”、“估计”、“预计”、“预测”、“目标”、“打算”、“或许”、“计划”、“可能”、“潜在”、“寻求”、“将”等词语或这些词语的变体或类似表达来识别，这些词语旨在识别前瞻性陈述。

Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected closing of the private placement, development of the Company's proprietary filaggrin protein and peptide technologies, and statements about our clinical and preclinical programs, and corporate and clinical/preclinical strategies..

本新闻稿中的任何非历史事实的声明均可被视为前瞻性声明。这些前瞻性声明包括但不限于关于私募配售预计完成时间、公司专有的聚丝蛋白和肽技术的发展、我们的临床和临床前项目以及公司和临床/临床前战略的声明。

Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.

本新闻稿中的任何前瞻性陈述仅基于本发布日期的当前预期、估计和预测，并受多种风险和不确定性的制约，这些风险和不确定性可能导致实际结果与这些前瞻性陈述中所述或暗示的结果存在重大且不利的差异。

These risks and uncertainties include, but are not limited to: conditions to the closing of the private placement, the receipt of stockholder approval, the exercise of the Warrants upon receipt of stockholder approval, we may fail to successfully complete our Phase 1b trial for ATR-12 program; we may experience delays in the dosing of our first patient in our Phase 1/2 trial for our ATR-04 program; our product candidates may not be effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing.

这些风险和不确定性包括但不限于：私募完成的条件、股东批准的获得、在获得股东批准后行使认股权证，我们可能无法成功完成ATR-12项目的1b期试验；我们在ATR-04项目1/2期试验中对首位患者的给药可能出现延迟；我们的候选产品可能无效；监管审批可能出现延迟或发生超出我们控制范围的监管框架变化；我们对候选产品可覆盖市场的估计可能不准确；我们可能无法及时筹集额外所需资金；可能出现更高效的竞争对手或更有效的竞争性治疗手段；我们可能卷入围绕对我们成功至关重要的知识产权使用的争议；我们可能无法吸引并留住关键员工和合格人员；早期研究结果可能无法预测后期研究的结果；我们在产品生产、研究以及临床前和临床测试的一些或所有方面依赖第三方。

Additional risks concerning Azitra's programs and operations are described or incorporated by reference in our annual report on Form 10-K filed with the SEC on February 27, 2026. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent requ.

有关 Azitra 项目和运营的其他风险在我们于2026年2月27日向美国证券交易委员会提交的Form 10-K年度报告中有所描述或引用。Azitra 明确声明，除非法律要求，否则不承担更新任何前瞻性陈述的义务。

Contact

联系

Norman Staskey

诺曼·斯塔斯基

Chief Financial Officer

首席财务官

[email protected]

电子邮件地址

Investor Relations

投资者关系

Tiberend Strategic Advisors, Inc